ArticleJournal of translational medicine2026
SERPINA4 facilitates colorectal cancer progression through m⁶A-dependent stabilization.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Serine protease inhibitors (SERPINs) have emerged as potential regulators in tumor progression, yet the specific function and regulatory mechanisms of SERPINA4 in CRC remain poorly characterized.
methodsWe integrated transcriptomic data from multiple CRC cohorts and conducted survival, pathway, and immune correlation analyses. Functional validation was performed using in vitro proliferation, migration, and invasion assays, as well as in vivo xenograft models. Post-transcriptional regulation of SERPINA4 via m6A modification was examined through MeRIP-qPCR, RNA immunoprecipitation, and decay assays.
resultsHigh expression of SERPINA4 was significantly associated with poor prognosis across multiple survival endpoints. SERPINA4 overexpression promoted CRC cell growth and metastasis in vitro and enhanced tumor formation in vivo. Mechanistically, ALKBH5-mediated m⁶A demethylation reduced SERPINA4 transcript stability by weakening IGF2BP3 association. Rescue experiments with methylation-deficient mutants confirmed the necessity of m6A for SERPINA4-driven oncogenicity. Moreover, SERPINA4 expression correlated with immunosuppressive signatures and reduced CD8 + T cell infiltration.
conclusionsOur findings reveal that SERPINA4 facilitates CRC progression through both tumor-intrinsic mechanisms and modulation of the immune microenvironment. These findings support an epitranscriptomic regulatory mechanism involving an ALKBH5–m6A–IGF2BP3 axis in CRC. SERPINA4 may serve as a prognostic biomarker and therapeutic target in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.